Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04592653
Title	Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3)
Acronym	ARTISTRY-3
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Alkermes, Inc.
Indications	head and neck squamous cell carcinoma mucosal melanoma triple-receptor negative breast cancer esophageal cancer cervical cancer Advanced Solid Tumor breast cancer fallopian tube cancer gastroesophageal adenocarcinoma biliary tract cancer pancreatic cancer lung small cell carcinoma ovarian cancer skin melanoma peritoneum cancer stomach cancer colorectal cancer renal cell carcinoma endometrial cancer lung non-small cell carcinoma
Therapies	ALKS 4230 ALKS 4230 + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| ESP